中山肛门有痔疮怎么治(中山咋治大便带血) (今日更新中)

The US Justice Department announced Friday an award of nearly million to help survivors of the 2017 mass shooting at Las Vegas' Route 91 Harvest music festival.Funding from the department's Office for Victims of Crime will help cover the costs of counseling, therapy, rehabilitation, trauma recovery and legal assistance for victims of the deadliest mass shooting in US history. Survivors covered by this award include ticket holders, concert staff, vendors, witnesses, law enforcement and other first responders, according to a DOJ statement.The .7 million award will also support close family members, medical personnel, coroner's staff, taxi drivers and others who helped concert goers on the October 2017 night in which 58 people were killed and hundreds of others wounded, according to the statement."While we cannot undo the harm that has been done, this Department of Justice is doing what we can to help Las Vegas heal," Acting Attorney General Matthew Whitaker said in the statement.On October 1, 2017, a reclusive high-stakes gambler named Stephen Paddock opened fire on the popular outdoor music festival from the 32nd floor of the Mandalay Bay Resort and Casino. The festival was attended by about 22,000.After the slaughter, Paddock, 64, was found dead on the floor of his hotel room with what appeared to be a self-inflicted gunshot wound to the head. 1380

The release of three US nationals currently detained in North Korea is "imminent," according to an official with knowledge of the ongoing negotiations.The official told CNN the North Koreans made the decision to free the Americans two months ago, and that North Korea's Foreign Minister Ri Yong Ho had proposed their release during his visit to Sweden in March.US officials insisted at the time that their release "must not be related or used to loosen the main issue of denuclearization," the source said. 519

The US Food and Drug Administration approved two cancer treatments, Vitrakvi and Xospata, this week after expedited reviews.Vitrakvi, approved Monday, is "a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker)."The FDA said in a statement that it is the second approved cancer treatment that is based on a tumor biomarker instead of the place in the body where the tumor originated.Vitrakvi will be used for the treatment of solid tumors that have an NTRK (neurotrophic receptor tyrosine kinase) gene fusion that do not have a known resistance mutation, that are not metastatic or where surgical removal is likely to lead to severe morbidity, and that have no alternative treatments or have progressed after treatments.NTRK genes are rare but occur in many types of cancer, the FDA said, such as mammary analogue secretory carcinoma and infantile fibrosarcoma.Xospata tablets, approved Wednesday, are for the "treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation," according to the FDA.Alongside the tablets, the agency also approved a diagnostic to detect the mutation."Approximately 25 to 30 percent of patients with AML have a mutation in the FLT3 gene. These mutations are associated with a particularly aggressive form of the disease and a higher risk of relapse," Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence, said in the statement.AML is a rapidly progressing cancer that affects the numbers of normal blood cells and calls for continuous transfusions, the FDA said.Both treatments were granted Priority Review designation.Priority Review, established in 1992, means the FDA aims to review the drug or treatment within six months, opposed to 10 months for a standard review."A Priority Review designation will direct overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications," the FDA says.Both treatments also received?orphan drug?designation, a status granted to drugs for rare diseases or conditions. 2261

The U.S. has now recorded at least 100,000 cases of COVID-19 each day for the last three weeks.On Monday, at least 169,190 new cases of the coronavirus were recorded throughout the U.S., marking 21 consecutive days that the country has seen at least 100,000 new COVID-19 cases.During that time span — dating back to Nov. 2 — the number of people in the country hospitalized with complications from the virus has nearly doubled from 48,557 to 85,836. Currently, about 69% of those hospitalizations are occurring in the South and Midwest, meaning some hospitals in those areas — particularly rural hospitals — are currently operating at capacity.The massive spike in cases has also caused the number of deaths linked to COVID-19 on a rolling 7-day average to nearly doubled from 826 a day to 1,515 a day. The last time the U.S. saw as many deaths per day as it sees now came back in mid-May when the country was still recovering from the virus' silent and uncontained spread in early spring. Over the weekend, the U.S. surpassed 3 million new cases in November alone. The country has recorded 12.4 million cases of COVID-19 since the pandemic began, meaning about one-quarter of all of those cases have occurred this month alone.Despite the bleak outlook on the state of the pandemic in the country, Dr. Anthony Fauci, the county's top expert on infectious diseases, warned Monday that the pandemic could worsen further. He said that if Americans don't follow common-sense public safety measures on Thanksgiving, cases could spike even further in December."The chances are that you will see a surge superimposed on a surge," Fauci said.Fauci recommends limiting Thanksgiving gatherings to members of a single household. He also says Americans need to continue to follow five common public safety measures in order to limit the spread: Adopt uniform mask-wearing, keep social distance, avoid large crowds, gather outdoors as opposed to indoors and continuously wash hands. 1983

The US Food and Drug Administration approved two cancer treatments, Vitrakvi and Xospata, this week after expedited reviews.Vitrakvi, approved Monday, is "a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker)."The FDA said in a statement that it is the second approved cancer treatment that is based on a tumor biomarker instead of the place in the body where the tumor originated.Vitrakvi will be used for the treatment of solid tumors that have an NTRK (neurotrophic receptor tyrosine kinase) gene fusion that do not have a known resistance mutation, that are not metastatic or where surgical removal is likely to lead to severe morbidity, and that have no alternative treatments or have progressed after treatments.NTRK genes are rare but occur in many types of cancer, the FDA said, such as mammary analogue secretory carcinoma and infantile fibrosarcoma.Xospata tablets, approved Wednesday, are for the "treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation," according to the FDA.Alongside the tablets, the agency also approved a diagnostic to detect the mutation."Approximately 25 to 30 percent of patients with AML have a mutation in the FLT3 gene. These mutations are associated with a particularly aggressive form of the disease and a higher risk of relapse," Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence, said in the statement.AML is a rapidly progressing cancer that affects the numbers of normal blood cells and calls for continuous transfusions, the FDA said.Both treatments were granted Priority Review designation.Priority Review, established in 1992, means the FDA aims to review the drug or treatment within six months, opposed to 10 months for a standard review."A Priority Review designation will direct overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications," the FDA says.Both treatments also received?orphan drug?designation, a status granted to drugs for rare diseases or conditions. 2261

来源：资阳报